Skip to main content
. 2018 Nov 16;3(11):15643–15652. doi: 10.1021/acsomega.8b02092

Figure 1.

Figure 1

Schematic diagram illustrating the interplay between the druggability and conservation of cavities in IDPs. Type-I cavities maintain good conservation but poor druggability. Type-II cavities maintain druggability but have low structural conservation for the binding site because of conformational changes. Type-III cavities keep both good druggability and conservation, which are ideal drug targets.